Baxendale Ian R, Braatz Richard D, Hodnett Benjamin K, Jensen Klavs F, Johnson Martin D, Sharratt Paul, Sherlock Jon-Paul, Florence Alastair J
Department of Chemistry, University of Durham, Durham DH1 3LE, UK.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139, Massachusetts, USA.
J Pharm Sci. 2015 Mar;104(3):781-791. doi: 10.1002/jps.24252. Epub 2016 Jan 8.
This whitepaper highlights current challenges and opportunities associated with continuous synthesis, workup, and crystallization of active pharmaceutical ingredients (drug substances). We describe the technologies and requirements at each stage and emphasize the different considerations for developing continuous processes compared with batch. In addition to the specific sequence of operations required to deliver the necessary chemical and physical transformations for continuous drug substance manufacture, consideration is also given to how adoption of continuous technologies may impact different manufacturing stages in development from discovery, process development, through scale-up and into full scale production. The impact of continuous manufacture on drug substance quality and the associated challenges for control and for process safety are also emphasized. In addition to the technology and operational considerations necessary for the adoption of continuous manufacturing (CM), this whitepaper also addresses the cultural, as well as skills and training, challenges that will need to be met by support from organizations in order to accommodate the new work flows. Specific action items for industry leaders are.
本白皮书重点介绍了与活性药物成分(原料药)的连续合成、后处理及结晶相关的当前挑战和机遇。我们描述了每个阶段的技术和要求,并强调了与间歇式工艺相比,开发连续工艺时的不同考量因素。除了为连续原料药生产提供必要化学和物理转化所需的特定操作顺序外,还考虑了采用连续技术可能如何影响从发现、工艺开发到放大生产再到全面生产的不同开发制造阶段。同时强调了连续制造对原料药质量的影响以及控制和工艺安全方面的相关挑战。除了采用连续制造(CM)所需的技术和操作考量外,本白皮书还探讨了文化以及技能和培训方面的挑战,组织需要提供支持以应对这些挑战,从而适应新的工作流程。行业领导者的具体行动项目如下。